Johannes Schetelig on remission induction versus immediate allogeneic HSCT for patients with AML

Professor Johannes Schetelig joins us to discuss the results of the ASAP phase 3 trial comparing remission induction with immediate allogeneic haematopoietic stem cell transplantation for patients with relapsed or poor responsive acute myeloid leukaemia.

Read the full article:
https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(24)00065-6/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanhae

Continue this conversation on social!
Follow us today at...
https://twitter.com/thelancet
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv